Skip to main content

Table 2 Treatment characteristics of re-irradiation for recurrent or second primary H&N cancer

From: The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer

Variable

Median (Range)

Time between 1st and 2nd radiotherapy

17 months (4–176 months)

Initial radiation dose, EQD2 (α/β = 10)

68.0 Gy (30.8 Gy – 72.0 Gy)

Re-irradiation dose, EQD2 (α/β = 10)

58.4 Gy (3.7 Gy – 66.0 Gy)

Re-irradiation dose for RT completion group, EQD2 (α/β = 10)

58.4 Gy (30.1 Gy – 66.0 Gy)

Re-irradiation dose for the RT non-completion group, EQD2 (α/β = 10)

27.45 Gy (3.7 Gy – 47.8 Gy)

Intended re-irradiation dose for the non-completion group, EQD2 (α/β = 10)

58.4 Gy (49.6 Gy − 66.0 Gy)

Cumulative radiation dose, EQD2 (α/β = 10)

122.8 Gy (63.7 Gy – 132.0 Gy)

Cumulative radiation dose for the boost-group, EQD2 (α/β = 10)

124.0 Gy (89.2 Gy – 132.0 Gy)

Cumulative radiation dose for the no boost-group, EQD2 (α/β = 10)

119.1 Gy (63.7 Gy – 131.6 Gy)

PTV

105.1 cm3 (16.7 cm3–905.3 cm3)

Cumulative Dmaxspinal cord, EQD2 (α/β = 3)

41.0 Gy (9.9 Gy – 74.8 Gy)

 

n

%

Radiotherapy

 definitive

31

64.6

 adjuvant

17

35.4

Completion radiotherapy

 no

6

12.5

 yes

42

87.5

Boost

 no boost

33

68.8

 integrated boost

10

20.8

 sequential boost

5

10.4

Simultaneous chemotherapy

 no

20

41.7

 yes

28

58.3

Chemotherapy,n = 28

 cetuximab

17

60.7

 cisplatin

8

28.6

 cisplatin/5-fluorouracil

1

3.6

 cisplatin/cetuximab

1

3.6

 carboplatin

1

3.6